SCHEMBL4566622

SCHEMBL4566622

CCn1c(=O)c(-c2cc(NC(=O)Nc3cc(C(F)(F)F)no3)c(F)cc2C)cc2cnc(NC)cc21

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 10/20 0.70
RAF1 P04049 9/20 0.70
KRAS P01116 7/20 0.70
KDR P35968 7/20 0.70
MAP2K2 P36507 5/20 0.70
MAP2K1 Q02750 5/20 0.70
KIT P10721 1/20 0.59
PDGFRA P16234 1/20 0.59
ARAF P10398 2/20 0.46
SRC P12931 7/20 0.42
BTK Q06187 6/20 0.42
LYN P07948 4/20 0.40
MAPK13 O15264 1/20 0.39
ABL1 P00519 1/20 0.39
FYN P06241 1/20 0.39
EPHA2 P29317 1/20 0.39
CSK P41240 1/20 0.39
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39
IRAK1 P51617 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4275132 0.94 BRAF (0.80) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5061892 0.90 BRAF (0.57) BRAFRAF1KRASKDRMAP2K2
SCHEMBL4277051 0.89 BRAF (0.68) BRAFRAF1KRASKDRMAP2K2
SCHEMBL4552966 0.87 BRAF (0.78) BRAFRAF1KRASKDRMAP2K2
SCHEMBL4279560 0.87 BRAF (0.69) BRAFRAF1KRASKDRMAP2K2
SCHEMBL4553396 0.85 RAF1 (0.73) BRAFRAF1KRASKDRMAP2K2
SCHEMBL22538358 0.85 RAF1 (0.80) BRAFRAF1KRASKDRMAP2K2
SCHEMBL14999824 0.84 RAF1 (0.78) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5061289 0.84 BRAF (0.65) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5065274 0.84 BRAF (0.65) BRAFRAF1KRASKDRMAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US claimed
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KRAS 30/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KRAS 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.